Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Improving Risk Assessment of Acute Myeloid Leukemia (AML) With a Precision Genomic Strategy to Assess Mutation Clearance

Research Question:
In patients who have been treated with standard consolidation chemotherapy and cleared their leukemia-associated mutations, is relapse-free and overall survival superior to what is expected based on historical controls?

Basic Study Information

Purpose:
The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is expected based on historical controls. The investigators will also prospectively determine the relapse-free and overall survival of patients who have not cleared their mutations. Because the relapse rate of patients with persistent mutations is expected to be high, treatment with either standard of care consolidation therapy alone or alloSCT will be permitted, at the discretion of the treating physician.

Location: University of Rochester Medical Center
Study Reference #: ULEU18122

Lead Researcher (Principal Investigator)

Lead Researcher: Eric Huselton

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 275-9485
Email: Haley_Misch@URMC.Rochester.edu

Additional Study Details

Return to Search